Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Voyager Therapeutics, Inc. (VYGR : NSDQ)
 
 • Company Description   
Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.

Number of Employees: 101

 
 • Price / Volume Information   
Yesterday's Closing Price: $6.36 Daily Weekly Monthly
20 Day Moving Average: 453,830 shares
Shares Outstanding: 38.46 (millions)
Market Capitalization: $244.58 (millions)
Beta: 1.08
52 Week High: $10.60
52 Week Low: $2.46
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -14.97% -6.90%
12 Week 67.37% 88.10%
Year To Date 134.69% 186.71%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
64 SIDNEY STREET
-
CAMBRIDGE,MA 02139
USA
ph: 857-259-5340
fax: -
investors@voyagertherapeutics.com http://www.voyagertherapeutics.com
 
 • General Corporate Information   
Officers
Michael Higgins - Chief Executive Officer and President
Julie Burek - Vice President of Finance
Mark Levin - Director
Jim Geraghty - Director
Steven Hyman - Director

Peer Information
Voyager Therapeutics, Inc. (CORR.)
Voyager Therapeutics, Inc. (RSPI)
Voyager Therapeutics, Inc. (CGXP)
Voyager Therapeutics, Inc. (BGEN)
Voyager Therapeutics, Inc. (GTBP)
Voyager Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 92915B106
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/08/22
Share - Related Items
Shares Outstanding: 38.46
Most Recent Split Date: (:1)
Beta: 1.08
Market Capitalization: $244.58 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.56 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.71 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/08/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 3.22
Price/Cash Flow: -
Price / Sales: 7.75
EPS Growth
vs. Year Ago Period: 3.45%
vs. Previous Quarter: -473.33%
Sales Growth
vs. Year Ago Period: -89.88%
vs. Previous Quarter: -97.66%
ROE
03/31/22 - -76.83
12/31/21 - -66.35
09/30/21 - -76.02
ROA
03/31/22 - -34.93
12/31/21 - -34.52
09/30/21 - -41.59
Current Ratio
03/31/22 - 1.68
12/31/21 - 2.68
09/30/21 - 4.73
Quick Ratio
03/31/22 - 1.68
12/31/21 - 2.68
09/30/21 - 4.73
Operating Margin
03/31/22 - -224.48
12/31/21 - -190.30
09/30/21 - -584.71
Net Margin
03/31/22 - -224.48
12/31/21 - -190.30
09/30/21 - -584.71
Pre-Tax Margin
03/31/22 - -224.48
12/31/21 - -190.29
09/30/21 - -584.70
Book Value
03/31/22 - 1.97
12/31/21 - 2.50
09/30/21 - 2.30
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©